Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Nature Cancer|November 5, 2021
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancerPeter M K Westcott, Nathan J Sacks, Jason M Schenkel, et al.Journal of Medical Virology|September 19, 2022
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapyRuthMabel Boytz, Mikołaj Słabicki, Sita Ramaswamy, et al.Iscience|April 25, 2023
The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope proteinCharles Zou, Hojong Yoon, Paul M C Park, et al.Nature Genetics|September 14, 2023
Mismatch repair deficiency is not sufficient to elicit tumor immunogenicityPeter M K Westcott, Francesc Muyas, Haley Hauck, et al.Biorxiv : the Preprint Server for Biology|April 28, 2021
Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivoJ J Patten, Patrick T Keiser, Deisy Gysi, et al.Iscience|August 22, 2022
Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritizationJ J Patten, Patrick T Keiser, Deisy Morselli-Gysi, et al.Iscience|January 11, 2021
A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screeningChristoph Gorgulla, Krishna M Padmanabha Das, Kendra E Leigh, et al.Cell Death & Disease|March 25, 2021
Inhibition of HECT E3 ligases as potential therapy for COVID-19Giuseppe Novelli, Jing Liu, Michela Biancolella, et al.Molecular Cell|December 1, 2020
Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2Ryan M Hekman, Adam J Hume, Raghuveera Kumar Goel, et al.Pageof 3